Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference
On June 5, 2020, Arvinas (Nasdaq: ARVN) announced Dr. Ron Peck, Chief Medical Officer, will speak at the Goldman Sachs 41st Annual Global Healthcare Conference on June 11 at 4:40 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On June 5, 2020, Arvinas (Nasdaq: ARVN) announced Dr. Ron Peck, Chief Medical Officer, will speak at the Goldman Sachs 41st Annual Global Healthcare Conference on June 11 at 4:40 p.m. ET. A live audio webcast will be available here and on their website at www.arvinas.com.
Details
News Market Reaction – ARVN
The recorded move for ARVN in the trading session of this news was +8.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., June 05, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11 at 4:40 p.m. ET.
A live audio webcast of the presentation will be available here and on the Company’s website at www.arvinas.com. A replay of the webcast will be archived on the Arvinas website for 30 days following the presentation.
About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Contacts for Arvinas
Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com
Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.